Stock Analiz

Takeda Pharmaceutical Co. Ltd. (TAK) financials: revenue, earnings and cash flow

Fiscal 2017–2026 + TTM · from SEC filings · data as of November 16, 2026

Summary

Takeda Pharmaceutical Co.’s revenue went from $15.5B in fiscal 2017 to $28.3B in fiscal 2026, growth of about 6.9% a year.

Net income in fiscal 2026 was -$956M, a net margin of -3.4%; the best year in this period was 2021 with $3.4B.

Over the twelve months to September 30, 2026, revenue was $29.4B and net income $256M.

Free cash flow was $3.9B in fiscal 2026 and positive in 10 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2017: $15.5B172018: $16.6B182019: $18.9B192020: $30.3B202021: $28.9B212022: $29.3B222023: $30.2B232024: $28.2B242025: $30.7B252026: $28.3B26$28.3B
Net income
2017: $1.0B172018: $1.8B182019: $1.2B192020: $408M202021: $3.4B212022: $1.9B222023: $2.4B232024: $953M242025: $722M252026: -$956M26-$956M
Free cash flow
2017: $1.8B172018: $2.9B182019: $2.3B192020: $5.0B202021: $8.1B212022: $8.2B222023: $6.3B232024: $3.6B242025: $5.7B252026: $3.9B26$3.9B
EPS (diluted)
2017: $0.33172018: $0.56182019: $0.39192020: $0.13202021: $1.07212022: $0.60222023: $0.75232024: $0.30242025: $0.23252026: $-0.3026$-0.30

Income statement

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$29.4B$28.3B$30.7B$28.2B$30.2B$29.3B$28.9B$30.3B$18.9B$16.6B$15.5B
Gross profit——$20.1B$18.8B$20.9B$20.2B$19.9B$20.3B$13.0B$12.0B$10.5B
Operating income——$2.3B$1.4B$3.7B$3.8B$4.6B$925M$2.1B$2.3B$1.4B
Net income$256M-$956M$722M$953M$2.4B$1.9B$3.4B$408M$1.2B$1.8B$1.0B
EPS (diluted)$0.08$-0.30$0.23$0.30$0.75$0.60$1.07$0.13$0.39$0.56$0.33
R&D———————————
Revenue growth—−7.8%+8.7%−6.7%+3.2%+1.6%−4.8%+60.2%+13.8%+7.4%—

Cash flow

Fiscal yearTTM2026202520242023202220212020201920182017
Operating cash flow$5.5B$6.5B$7.1B$4.7B$7.3B$9.2B$9.1B$6.2B$3.0B$3.5B$2.3B
Capital spending-$2.8B-$2.6B-$1.3B-$1.2B-$1.1B-$1.0B-$1.0B-$1.2B-$701M-$630M-$551M
Free cash flow$2.7B$3.9B$5.7B$3.6B$6.3B$8.2B$8.1B$5.0B$2.3B$2.9B$1.8B
Dividends paid$2.0B$2.0B$2.0B$1.9B$2.1B$2.3B$2.6B$2.6B$1.3B$1.3B$1.3B
Buybacks——$347M$15M$202M$637M$19M$34M$11M$176M$207M
Stock-based pay———————————

Balance sheet

Fiscal yearTTM2026202520242023202220212020201920182017
Cash—$2.6B$2.6B$3.0B$4.0B$7.0B$8.7B$5.9B$6.3B$2.8B$2.9B
Debt—$30.2B$30.2B$32.0B$32.9B$35.7B$41.8B$46.9B$51.9B$9.3B—
Equity—$46.4B$46.4B$48.1B$47.7B$46.7B$46.7B$43.5B$46.8B$18.8B$17.4B
Total assets—$95.4B$95.4B$99.9B$104.8B$108.2B$116.5B$118.1B$124.5B$38.6B—
Shares (diluted)3.17B3.21B3.16B3.16B3.16B3.16B3.16B3.16B3.16B3.16B3.16B

Margins and returns

Fiscal yearTTM2026202520242023202220212020201920182017
Gross margin——65.5%66.5%69.1%69.0%68.9%66.9%68.9%72.0%67.7%
Operating margin——7.5%5.0%12.2%12.9%15.9%3.0%11.3%13.7%9.0%
Net margin0.9%-3.4%2.4%3.4%7.9%6.5%11.8%1.3%6.5%10.6%6.6%
FCF margin9.2%13.9%18.7%12.7%20.8%28.0%28.1%16.5%12.0%17.6%11.5%
ROIC——1.8%1.4%3.9%3.5%4.1%0.8%1.7%7.0%6.4%
ROE——1.6%2.0%5.0%4.0%7.3%0.9%2.6%9.4%5.9%

Frequently asked questions

What is Takeda Pharmaceutical Co.’s annual revenue?

$28.3B in fiscal 2026 and $29.4B over the twelve months to September 30, 2026.

How much profit does Takeda Pharmaceutical Co. make?

Net income was -$956M in fiscal 2026 (net margin -3.4%).

Is Takeda Pharmaceutical Co.’s revenue growing?

No: revenue fell 7.8% in fiscal 2026 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.